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Abstract
Astrocytes are the most abundant cell type in the brain. They were long considered only as passive support for neuronal 
cells. However, recent data have revealed many active roles for these cells both in maintenance of the normal physiological 
homeostasis in the brain as well as in neurodegeneration and disease. Moreover, human astrocytes have been found to be 
much more complex than their rodent counterparts, and to date, astrocytes are known to actively participate in a multitude 
of processes such as neurotransmitter uptake and recycling, gliotransmitter release, neuroenergetics, inflammation, modu-
lation of synaptic activity, ionic balance, maintenance of the blood–brain barrier, and many other crucial functions of the 
brain. This review focuses on the role of astrocytes in human neurodegenerative disease and the potential of the novel stem 
cell-based platforms in modeling astrocytic functions in health and in disease.
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Abbreviations
AD  Alzheimer’s disease
ALS  Amyotrophic lateral sclerosis
APP  Amyloid precursor protein
ARE  Antioxidant response element
BBB  Blood–brain barrier
CNS  Central nervous system
EC  Endothelial cells
ES  Embryonic stem
GDNF  Glial cell line-derived neurotrophic factor
MERTK  Mer proto-oncogene tyrosine kinase
MS  Multiple sclerosis
PD  Parkinson’s disease
PET  Positron emission topography
PPP  Pentose phosphate pathway
RC  Respiratory chain
RET  Reverse electron transport
ROS  Reactive oxygen species
VEGF  Vascular endothelial growth factor
Introduction
Astrocytes are the most abundant non-neuronal cell type 
in the central nervous system (CNS). They serve numerous 
critical functions in the brain, including regulation of syn-
apse formation and pruning, as well as regulation of neuroin-
flammation and lactate and glutamate levels in the brain [1]. 
Astrocytes play a key role also in several homeostatic and 
neuroprotective functions and are essential for the integrity 
of the blood–brain barrier (BBB). Primary astrocyte defects 
have been implicated to impact neurodegenerative diseases, 
and both a loss of their normal supportive function as well as 
a gain of toxic functions are thought to underlie the neuronal 
death in acute or chronic brain diseases [2, 3]. This review 
will address the main functions of astrocytes involved in 
neurodegeneration.
Astrocytes in synaptic defects
Synaptic dysfunction and degeneration are common features 
in many neurodegenerative diseases, such as Alzheimer’s 
disease (AD), and amyotrophic lateral sclerosis (ALS). 
Synaptic defects establish in the early stages of the diseases 
and synapse loss is often considered a primary pathological 
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feature and not just secondary to the typical neuron loss in 
these diseases.
Astrocytes are part of the tripartite synapse
Astrocytes have critical roles in controlling synaptic 
development, functionality, plasticity, and elimina-
tion (reviewed in Ref. [4]). First of all, the presence of 
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astrocytes is required for synapse formation, and glial 
depletion results in loss of synaptic connections followed 
by neurodegeneration. Astrocytes secrete synaptogenic 
factors, including thrombospondins, which regulate the 
number and formation of synapses [5, 6]. In addition to the 
secreted signaling molecules, a direct contact of neurons 
with astrocytes seems to be essential for synapse forma-
tion [6]. Second, astrocytes regulate the functionality of 
synapses in many ways. They contact and ensheath the 
pre- and post-synaptic endings of neurons in the human 
brain [7] and communicate with them to form the tripartite 
synapse [8] (Fig. 1a). Astrocytes fine-tune the strength 
of synaptic signals by regulating the pre-synaptic vesicle 
release and post-synaptic receptor composition through 
secreted molecules [4]. For example, astrocyte-secreted 
cholesterol has been shown to enhance pre-synaptic gluta-
matergic signaling [9]. Astrocytes also provide structural 
support and produce many cell adhesion and extracellu-
lar matrix-related molecules (e.g., neuroligins, cadherins, 
glypicans, and laminins) required for proper synapse for-
mation and function (reviewed in Ref. [10]). In addition, 
astrocytes and astrocyte-secreted factors play a role in the 
different aspects of neuronal circuits and synaptic plastic-
ity, including long-term potentiation, long-term depres-
sion, and synaptic scaling. Astrocytes are capable of regu-
lating and clearing neurotransmitters in the synaptic cleft, 
but they also communicate by secreting the so-called gli-
otransmitters (e.g., GABA, glutamate, d-serine, and ATP) 
as a result of increased intracellular  Ca2+ levels. These 
gliotransmitters act on various excitatory and inhibitory 
targets and are known to modulate synaptic transmission 
and plasticity (reviewed in Ref. [11]). The recent find-
ing that transplantation of human astrocytes significantly 
improves the cognitive behavior of mice further supports 
the role of astrocytes in synaptic plasticity and cognition 
[12]. Finally, astrocytes have been shown to participate in 
synapse elimination and pruning, and thus refinement of 
neuronal circuits, through phagocytosis [13]. This process 
is regulated by two phagocytic receptor pathways, mul-
tiple EGF-like domains 10 (MEGF10) and c-mer proto-
oncogene tyrosine kinase (MERTK) at least in mice. Taken 
together, astrocytes are constantly monitoring and regu-
lating synapses in many ways through direct contact and 
various signaling molecules, and thus, they are likely to 
play an essential role in synaptic defects linked to neuro-
degenerative disorders.
Astrocytes are linked to synaptic defects 
in neurodegenerative diseases
The best evidence for synaptic defects in neurodegenerative 
diseases comes from AD studies. In AD, synapse dysfunc-
tion is one of the most striking early pathological features. 
There is a progressive loss of synapses during the disease 
course, and in fact, the extent of synapse loss is the best 
correlate with cognitive decline [14]. The exact mechanisms 
behind the synapse loss and synaptic defects still remain 
Fig. 1  a Astrocytes and the pre- and post-synaptic endings of neurons 
form the tripartite synapse. Astrocytes clear neurotransmitters and 
secrete gliotransmitters, e.g., GABA, glutamate, d-serine, and ATP 
[5, 6]. In addition, they provide structural support and produce many 
cell adhesion and extracellular matrix-related molecules required for 
proper synaptic function. In AD, APOE4 astrocytes have decreased 
rate of synapse pruning and turnover in the brain [18]. In AD expres-
sion of GABA, the inhibitory gliotransmitter, in reactive astrocytes, 
is increased, whereas reduced other gliotransmitter release, especially 
ATP [22–24]. b Blood–brain barrier. Astrocytic perivascular endfeet 
express water channel aquaporin-4 (AQP4) and the ATP-sensitive 
inward rectifier potassium channel Kir4.1, and transporter proteins 
such as glucose transporter-1 and P-glycoprotein [37]. Astrocytes 
support the BBB through the release of several growth factors includ-
ing vascular endothelial growth factor (VEGF), glial cell line-derived 
neurotrophic factor (GDNF), basic fibroblast growth factor (bFGF), 
and angiopoietin 1 (ANG-1) [41]. Astrocytes communicate with each 
other through gap junction proteins mainly connexin (Cx) 43 and Cx 
30. Astrocytic APOE4 promotes BBB disruption in AD. The release 
of pro-inflammatory cytokines including IL-6, IL-1B, and TNF-A in 
PD increase neuronal death and rearrange TJ protein expression on 
ECs. Astrocyte ability to maintain water and potassium homeostasis 
is reduced in ALS due to increased expression of AQP4 and reduced 
Kir4.1 [75]. c Astrocytes provide metabolic support to the neurons 
and maintain neurotransmitter homeostasis, actively responding on 
neuronal signals [86]. In neurodegenerative disease, these functions 
are compromised. Astrocytes exposed to amyloid peptides alter glu-
cose uptake and its downstream metabolism in parallel with increased 
hydroperoxide and glutathione release. AD impacts astrocytic metab-
olism causing increased glutamate and ATP release, what in turn 
results in stimulation of microglial activation and neuronal vulnera-
bility [101]. Astrocytic expression of PD-related A53T mutant alpha-
synuclein results in down regulation of glutamate transporters and 
wide-spread gliosis [108]. In ALS, chronic activation of the α2-Na/K 
ATPase/α-adducin complex in astrocytes has been demonstrated, 
resulting in biased energy metabolism and acquisition of pro-inflam-
matory phenotype [131]. d Astrocytes mediate inflammatory effects 
in neurodegeneration. Astrocytic activity is affected by plethora of 
cytokines; INF-γ, IL-1β, IL-6, and TNF-α lead to classical activation, 
whereas IL-10, IL-4, and IL-13 induce alternative activation with 
decreased ROS and NO production alleviating inflammation [139]. In 
addition, astrocytes release factors affecting their inflammatory envi-
ronment. Different cytokine levels are known to be affected in neuro-
degenerative disorders. In AD, astrocyte associated inflammation has 
been linked to IL-1β, IL-6, TNF-α, and TGF-β leading to activation 
of microglial cells [145]. Whereas, levels of IL-1β, TGF-β, and IFNs 
have been demonstrated to be elevated in post-mortem tissues of 
ALS patients [161]. Finally, in PD, levels of IL-1β, TNF-α, and IFN- 
γ are shown to be affected [153, 154]. e Astrocytes and oxidative 
stress in neurodegenerative diseases. In normal physiological condi-
tions, astrocytes are glycolytic, whereas neurons are more oxidative 
and produce much more ROS than astrocytes do; however, increased 
ROS production by astrocytes has been reported in both AD and ALS 
[187, 196]. On the other hand, astrocytes have much higher antioxi-
dant capacity than neurons and express higher levels of Nrf2, catalase 
and GSH, than neurons. Oxidative stress induces GSH release from 
astrocytes, which is degraded, and the cysteine-rich degradation prod-
ucts are taken up by neurons and used for neuronal GSH synthesis. 
[198–200]
◂
2742 M. Oksanen et al.
1 3
unclear, although several theories involving beta-amyloid 
(Aβ) plaques, complement cascade pathway, and microglia 
have been proposed [15] [16]. In addition, the importance of 
astrocytes in AD and synaptic defects is currently strongly 
emerging and this review will address some of the recent 
advances supporting it. For example, astrocyte-derived cho-
lesterol has been shown to be a crucial factor in promot-
ing synaptogenesis [9]. Apolipoprotein E (apoE), the major 
cholesterol carrier in the brain, is mainly synthesized and 
secreted by astrocytes. APOE polymorphisms are the main 
genetic determinants for AD with the APOE4 allele being 
associated with increased AD risk [17]. In mouse studies, 
APOE4 astrocytes showed decreased rate of synapse prun-
ing and turnover in the brain, leading to the accumulation 
of senescent, non-functional synapses, when compared 
to APOE3 astrocytes [18]. This could be linked to the 
increased synaptic vulnerability in AD. Zhao and colleagues 
used human iPSC-derived neurons and astrocytes in a tran-
swell-based co-culture system to study the effects of APOE4 
astrocytes on control neurons [19]. They found that APOE4 
astrocytes were less capable of promoting synapse formation 
and the expression of synaptic proteins was decreased in 
comparison with APOE3 astrocytes. Furthermore, APOE4 
astrocytes reduced the survival of neurons and eventually 
led to neurodegeneration. These data support the importance 
of astrocytes and APOE genotype in synaptic deficiencies 
and neurodegeneration linked to AD. Another astrocyte-
secreted synaptogenic molecule, thrombospondin-1 (TSP-1), 
has decreased expression level in the brain of AD patients 
[20]. On the other hand, treatment with TSP-1 was shown to 
reverse the Aβ-induced synaptic dysfunction in vivo.
Intriguingly, astrocytes were very recently found to engulf 
and phagocytose dystrophic neurons and pre-synaptic ele-
ments associated with amyloid plaques in APP/PS1 mutant 
AD mice as well as in post-mortem human brains [21]. This 
result supports the role of astrocytes in synaptic regulation 
and phagocytosis also in the human brain, although the exact 
meaning for disease pathogenesis remains to be elucidated. 
It is hypothesized that the astrocytic clearance of dystrophic 
neurites and dysfunctional synapses is inadequate in AD, 
resulting in their accumulation and impaired neural net-
works. In mice, the rate of synapse pruning decreases upon 
aging leading to the accumulation of senescent synapses, a 
possible explanation behind the cognitive decline [4, 13].
Reactive astrocytes in post-mortem AD patient’s brain show 
markedly increased expression of GABA, the inhibitory gli-
otransmitter. The enhanced GABA signaling has been linked 
with memory and learning deficits in mouse models of AD 
[22]. In addition, a specific type of reactive astrocytes shows 
diminished potential to promote synaptogenesis and synaptic 
function, leading to a decreased number of synapses with only 
weak signals and, finally, neurodegeneration [23]. This kind 
of reactive astrocytes seems to be abundant in post-mortem 
AD brain. In mouse primary hippocampal cultures, astrocytes 
internalized oligomeric tau, which was followed by reduced 
gliotransmitter release, especially ATP [24]. The reduced ATP 
release from astrocytes reduced the synaptic transmission of 
neurons and expression of both pre- and post-synaptic proteins 
in them.
In other neurodegenerative diseases, there is so far less evi-
dence supporting the role of astrocytes in synaptic defects. 
In ALS, astrocytes have a well-established role in the degen-
eration of motor neurons and astrocytes with both sporadic 
(sALS) and familial (fALS) background seem to have similar 
effects when studied either in vitro or in vivo [25–28]. ALS is 
characterized by synaptic disconnections at the neuromuscular 
junction leading to axonal degeneration and, finally, death of 
neurons through either cell-autonomous or non-cell-autono-
mous mechanisms [29]. When transplanted into the mouse 
spinal cord, human sALS astrocytes have been shown to lead 
to reduced pre-synaptic connections and denervation at the 
neuromuscular junctions [28]. There is also a significant loss 
and degeneration of synapses in the frontal cortex in ALS, but 
this has not been clearly linked to astrocytes or astrogliosis in 
the post-mortem human brain [30].
In synucleinopathies such as Parkinson’ disease (PD) and 
dementia with Lewy bodies (DLB), a pre-synaptic protein 
α-synuclein aggregates to form insoluble fibrils. Recently, 
numerous small deposits of α-synuclein aggregates that are 
not associated with Lewy bodies were demonstrated at the 
presynapses in PD DLB cases. Moreover, dendritic spines 
showed retraction, whereas the presynapses were mostly 
preserved, suggesting a neurotransmitter deprivation [31]. 
As α-synuclein released from neuronal cells can be taken 
up by astrocytes and induce inflammatory response and 
reduced release of neurotrophic factors, astrocytes may regu-
late synaptic functions related to pre-synaptic deposition of 
α-synuclein (Table 1).
In Huntington’s disease patients, reduced glutamate 
uptake has been detected and this is linked to astrocytes, 
since glutamate is cleared from the perisynaptic area mostly 
by astrocytes [32]. In Down’s syndrome, there is reduced 
level of astrocyte-secreted TSP-1 leading to decreased syn-
aptic density and spine malformations [33]. Taken together, 
these findings support the importance of astrocytes, astro-
cyte-secreted gliotransmitters, and other factors in synapse 
defects and neurodegeneration, although more human stud-
ies are needed for confirmation.
Astrocytes in the maintenance of the blood–
brain barrier in neurodegenerative diseases
The blood–brain barrier (BBB) is a semipermeable mem-
brane that separates the circulating blood from the CNS. 
It regulates delivery of oxygen and important nutrients 
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to the brain through active and passive transport and pre-
vents neurotoxins from entering the brain. It also has a 
clearance function and removes carbon dioxide and toxic 
metabolites from the CNS. A well-functioning BBB is 
essential for maintaining healthy brain tissue, and BBB 
breakdown or dysfunction is associated with a variety of 
neurological diseases due to the accumulation of blood-
derived neurotoxins in the CNS that causes progressive 
Table 1  Astrocyte dysfunctions in neurodegenerative pathologies
Neurodegenerative pathology Disease Pathological hallmark/mechanism proposed References
1. Synaptic pathology AD Decreased rate of synapse pruning [18]
Increased expression of GABA [22]
Reduced gliotransmitter ATP release [24]
PD α-Synuclein aggregates in the synaptic terminals [31]
ALS Reduced pre-synaptic connections and NMJ denervation [28]
2. BBB dysfunction AD BBB leakage due to loss of tight junction barrier function [61, 63, 64]
Endfeet retraction and reduced expression of GLUT1 and lactate transporters [54]
AQP4 deficient mice are unable to clear soluble Aβ [38]
Astrocytic APOE4 accelerates pericyte loss and microvascular reduction [57]
PD Increased permeability of the BBB associated with decreased expression of P-glyco-
protein
[65, 66]
ALS BBB disturbances in both sALS and patients with SOD1 mutation [71]
Increased AQP4-promoted perivascular edema-linked BBB opening [74, 75]
3. Metabolic dysfunction AD Triggering amyloid beta deposition [97] [188]
Metabolically regulation of beta and gamma secretase levels [98, 99]
Aberrant post-translational modification of APP [100]
Altered glucose uptake and metabolism in parallel with increased hydroperoxide and 
glutathione release
[101]
Increased glutamate and ATP release through connexin 43 hemichannels [102, 103]
PD Astrocytic expression of mutant alpha-synuclein resulted in down regulation of gluta-
mate transporters
[108]
ALS Impaired supportive capacity to motor neurons [117, 118]
Disruption of the TCA cycle and glutamate metabolism [126]
Dysregulation of purine, pyrimidine, lysine, and glycerophospholipid metabolism 
pathways
[127]
Impairment of the astrocyte lactate transport and pro-nerve growth factor-p75 receptor 
signaling
[129]
Chronic activation of the α2-Na/K ATPase/α-adducin complex, resulting in biased 
energy metabolism
[131]
4. Oxidative stress AD Increased ROS due to activation of astrocytic NADPH oxidase [186]
Activated PARP, leading to decreased NAD levels and metabolic failure [187]
Increased ROS and  Ca2+ leakage from ER leading to opening of the mitochondrial 
permeability transition pore
[190]
PSEN1 mutant astrocytes manifest Aβ-deposits and altered metabolism with increased 
ROS production
[188]
ALS Increased ROS production which can be prevented by antioxidants [196]
5. Neuroinflammation AD Release chemokines, cytokines, and increase the production of Aβ in response [142]
Hypertrophic reactive astrocytes accumulate around the Aβ plaques [143]
Increase in reactive A1 astrocytes [23]
MAO-B highly expressed in astrocytes surrounding amyloid plaques [239]
PD Presence of reactive astrocytes in the substantia nigra pars compacta [148]
Genes implicated in PD pathology play a role in the astrocyte activation in response to 
inflammatory stimuli
[149–152]
ALS Pro-inflammatory mediators upregulated in ALS-patient tissues and stem-cell-derived 
human astrocytes
[113, 158–160]
A strong astrocytic A1-phenotype in the motor cortex of ALS patients [23]
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neurodegeneration [34]. Although the most important 
components of the BBB are endothelial cells (ECs), 
astrocytes contribute to BBB stability through their direct 
contact of perivascular endfeet with ECs and pericytes 
(Fig. 1b).
Astrocytes through their endfeet establish the link 
between the endothelial cells and neurons and are impor-
tant in the development and maintenance of BBB. Astro-
cytic perivascular endfeet surround ~ 98% of the basal 
parenchymal membrane of brain microvessels and express 
molecules which regulate ionic concentrations and pro-
tein transporters in the BBB [35, 36]. Among the most 
abundant ones are water channel aquaporin-4 (AQP4) 
and the ATP-sensitive inward rectifier potassium chan-
nel Kir4.1, as well as transporter proteins such as glucose 
transporter-1 and P-glycoprotein, indicating the impor-
tance of the endfeet polarization for proper functioning 
of BBB [37]. Interestingly, the location of AQP4 follows 
the distribution of inwardly rectifying potassium channel 
4.1 (Kir4.1) [38], and together, they control water balance 
and ion homeostasis at the level of BBB and neuronal syn-
apses [39, 40]. Furthermore, astrocytes support the BBB 
maintenance through the release of several growth factors, 
including vascular endothelial growth factor (VEGF), glial 
cell line-derived neurotrophic factor (GDNF), basic fibro-
blast growth factor (bFGF), and angiopoietin 1 (ANG-1) 
[41]. The upregulation of ANG-1 leads to enhanced bar-
rier tightness through increased expression of junctional 
proteins, such as occludin and claudins and inhibition of 
leukocyte transmigration after TNFα stimulation. The 
identification of astrocyte-secreted factors suggests that 
mature astrocytes rather modulate and maintain the bar-
rier function than induce its cerebrovascular integrity, 
because astrocytes initially appear at the neurovascular 
unit (NVU) postnatally [42]. Astrocytes regulate the blood 
flow according to demands of neuronal synaptic activity 
[43] by elevating  Ca2+ levels in the endfeet [44]. Depend-
ing on released mediators such as prostaglandin E, nitric 
oxide, or arachidonic acid from astrocytes, blood vessels 
in brain constrict or dilate [45, 46]. Astrocytes also pro-
duce a cholesterol and phospholipid transporter molecule 
APOE, which mediates regulatory processes related to 
brain homeostasis [47]. Adult ApoE knockout mice show 
increased permeability selectively of cerebral vessels 
and leakage of serum proteins into the CNS tissue [48]. 
Whereas APOE3, the most abundant human APOE iso-
form, and APOE2 mediate physiological BBB tightness, 
APOE4 promotes BBB disruption, as observed in mutant 
mice in which mouse Apoe was replaced by human APOE 
isoforms [49]. Thus, homeostasis of the neurovascular 
junction is fundamental for cognitive functions, and home-
ostatic imbalances may be linked to cognitive changes.
Astrocytes in BBB dysfunction
Reactive astrogliosis is a common feature of astrocytes and 
compromises neuronal survival. This process involves both 
molecular and morphological changes in astrocytes and 
highly depends on the events triggering it. Therefore, it may 
have both beneficial and detrimental effects on surrounding 
cells [50]. Astrocytes communicate with each other through 
gap junction proteins, mainly connexin (Cx) 43 and Cx 30. 
Mice lacking Cx43 and Cx30 expression on astrocyte end-
feet manifest a significant loss of AQP4 and β-dystroglycan, 
a transmembrane receptor anchoring astrocyte endfeet to the 
perivascular basal lamina. The absence of astroglial connex-
ins weakens the BBB that opens upon increased hydrostatic 
vascular pressure and shear stress [51].
Alzheimer’s disease
Accumulating data support the importance of vascular 
astrocytes in AD pathology [52, 53]. Astrocyte endfeet 
surrounding vascular Aβ deposits showed morphological 
changes including retraction and swelling, and reduced 
expression of GLUT1 and lactate transporters in transgenic 
arctic β-amyloid (arcAβ) mice expressing human amyloid 
precursor protein (APP) [54]. These changes occur at early 
stages of the disease and are consistent with NVU uncou-
pling, suggesting that astrocyte dysfunction contributes 
to the early behavioral and cognitive impairments. AQP4 
deficient mice are unable to clear soluble Aβ efficiently, 
proposing that this pathway may remove Aβ from the CNS 
[38]. In humans, the loss of perivascular AQP4 localization 
was associated with increased Aβ burden and increased AD 
pathology (Braak stage) [55]. Furthermore, primary human 
astrocytes obtained from non-demented human brain tissue 
upregulate the expression of neprilysin and scavenger recep-
tor B1 as a response to Aβ–APOE complexes. This function 
appears to be defective in astrocytes derived from AD brain 
[56]. APOE4, which in CNS is mainly secreted by astro-
cytes, accelerates pericyte loss and microvascular reduction 
by enhancing pro-inflammatory pathway both in pericytes 
and ECs [57]. These findings suggest that Aβ clearance of 
astrocytes is impaired in AD due to astrocyte polarization 
induced by brain Aβ deposition [58, 59]. Nevertheless, the 
contribution of Aβ-induced changes to BBB is still unclear.
AD patients’ brains are characterized by high prevalence 
of degenerated endothelium and impairment of BBB trans-
port system [34, 60]. BBB breakdown in the hippocampus 
precedes neurodegeneration [61, 62] and follow-up studies 
in AD patients have confirmed BBB leakage in both gray 
and white matter regions due to a loss of tight junction bar-
rier function [61, 63, 64]. Moreover, cognitive decline was 
associated with stronger BBB leakage in patients with an 
early AD, suggesting that BBB damage might be part of a 
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cascade of pathologic events that eventually leads to demen-
tia [61]. In aging brain, altered AQP4 expression and its 
redistribution from astrocytic endfoot membranes to non-
end-foot membranes compromise Aβ clearance through the 
glymphatic system and likely contribute to AD pathology 
[55].
Parkinson’s disease
Initially, it was assumed that the BBB stays unaltered dur-
ing the development of PD, but several studies with human 
and animal models have linked BBB dysfunction with the 
development of PD pathology. In studies with PD patients, 
the increased permeability of the BBB was associated with 
decreased expression of P-glycoprotein demonstrated by 
increased uptake of  [11C]-verapamil in the midbrain [65] 
and frontal white matter regions in PD patients [66]. Tak-
ing into account that P-glycoprotein is an active drug trans-
porter, it is possible that the reduction of P-glycoprotein 
may be associated with accumulation of neurotoxins and 
aggregated proteins in the PD brain affecting directly dopa-
minergic neuron survival [67]. In addition to human studies, 
several toxin-induced animal models, including 6-OHDA 
treated rats and MPTP-treated mice, have shown a disrup-
tion of the BBB that is linked to the loss of dopaminergic 
neurons [68, 69]. It has also been shown that activation of 
microglia and astrocytes in PD leads to the release of pro-
inflammatory cytokines, including IL-6, IL-1B, and TNFα, 
which can increase neuronal death and rearrange tight junc-
tion protein expression on ECs [70]. Moreover, the loss of 
signaling interaction between astrocytic perivascular endfeet 
and ECs leads to hypertrophy and upregulation of GFAP and 
vimentin in astrocytes triggering reactive astrogliosis and 
weakens BBB tightness [41].
Amyotrophic lateral sclerosis
In ALS, neurodegeneration of upper and lower motor neu-
rons in the brain and spinal cord is not completely under-
stood. The pathogenesis of the disease is complex with 
recent evidence showing BBB disturbances in the brain of 
fALS patients that carry SOD1 mutation and in post-mor-
tem brains of sALS patients [71]. Primary degeneration of 
ECs and pericytes compromising vascular barrier integrity 
both in the brain and spinal cord of ALS patients has been 
described. The BBB disruption could be the main obstacle 
for efficient drug delivery to the CNS due to the impairment 
of P-glycoprotein efflux transporter in the brain and spinal 
cord microvessels [72, 73]. Therefore, restoration of BBB 
integrity could promote delivery of therapeutics to the CNS 
as well as help to remove waste products from the brain, 
providing an improved environment for motor neuron sur-
vival. The astrocyte contribution to BBB disruption in ALS 
has been studied only in rodents. In end-stage SOD1, rats 
increased expression of AQP4 in the spinal cord gray mat-
ter and around blood vessels promoted perivascular edema-
linked BBB opening in ALS [74]. As elevated AQP4 was 
also detected near motor neurons, it is possible that dysfunc-
tional astrocytes contribute to further motor neuron degen-
eration [75]. In parallel Kir4.1 expression was decreased 
in the brainstem and cortex of SOD1 rats. Thus, ability of 
astrocytes to properly maintain water and potassium homeo-
stasis in CNS is reduced, not only affecting the BBB but also 
impeding motor neuron survival in ALS. In pre-symptomatic 
SOD1 mutant mice, BBB breakdown has been demonstrated 
prior to motor neuron degeneration and inflammatory 
changes in the spinal cord [76]. Whether connexin-mediated 
changes are directly affecting BBB function in ALS, is not 
known yet. However, although BBB damage might not be a 
causative event in ALS, it is still a significant, and possibly 
critical, pathologic effector for the disease progression.
In vitro models of the BBB
To better understand the role of human astrocytes in BBB 
functionality in neurodegenerative diseases and to develop 
new treatment strategies with predictive drug permeabil-
ity, there is a demand for development of improved BBB 
models which include astrocytes and other components of 
human origin. Current in vitro BBB models mostly use brain 
microvessels and astrocytes of bovine, porcine, or rodent 
origin [77]. Even though the models are well established, the 
characteristics and functionality of the BBB in these species 
differ from that in humans especially in the expression level 
of important transporters such as P-glycoprotein [78–81]. 
The first human BBB models were generated from primary 
and immortalized human cells [82, 83]. However, the lim-
ited availability of primary human cells and lack of bar-
rier tightness in immortalized cells underlines the need for 
more accessible and relevant cell source for BBB modeling. 
Recent advances in stem cell technology have created the 
opportunity to generate cells important for building human 
in vitro BBB [84, 85]. Stem cell sources have demonstrated 
a significant advantage over other cell types in respect of 
human origin, scalability, self-renewal, and potential to gen-
erate all BBB cell components from the same patient.
Metabolic dysfunction of astrocytes 
in neurodegenerative diseases
Astrocytes are actively participating in many metabolic 
functions of the CNS. Even though for the time being 
none of the human neurodegenerative diseases is known 
to originate from the astrocytic cell-autonomous dysfunc-
tion, astrocyte–neuronal metabolic coupling plays a central 
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role in the physiological CNS homeostasis (Fig. 1c). The 
role of astrocytes spans far beyond the participation in a 
tripartite synapse and astrocytes have an impact on vir-
tually every function classically attributed to neurons. 
Moreover, astrocytes provide metabolic and structural 
support to neuronal circuits. A recently discovered ability 
of astrocytes to regulate the respiratory rhythm-generating 
neuronal circuits through mechanism involving vesicular 
release indicates a key role of astrocytes in modulation of 
CNS activities [86].
The metabolic demand of CNS is very high, comprising 
approximately ten times over the average for all tissues. The 
major metabolic consumers here are the functions needed for 
maintenance of the membrane potential and ion transport 
across the membranes. On the other hand, the brain contains 
little substances for energy production and relays mainly on 
supplies from the circulation [87]. The main energy sub-
strate for the CNS function is glucose, in parallel with ketone 
bodies which complement energy source upon fasting [88]. 
Astrocytes are thought to be the main glucose utilizing cells 
converting it to lactate and pyruvate and creating glycogen 
deposits. Astrocytes are also capable of ketogenesis, which 
besides providing an alternative source for energy metabo-
lism may also protect against accumulation of non-esterified 
fatty acids and prevent formation of pro-apoptotic ceramide 
[89]. Providing anatomically a link between circulation and 
neuronal circuits, astrocytes serve as a major regulator of 
neuronal metabolism. All these activities are coupled and 
orchestrated with neuronal activity. Thus, astrocytes also 
support neurons by delivering substrates for energy metab-
olism, biosynthesis and neurotransmission, as well as take 
care of waste processing.
Even though neurons and astrocytes have an equal capac-
ity to fully oxidize both glucose and lactate, they demon-
strate physiological preferences resulting in astrocytes being 
mostly glycolytic in contrast to neurons that favor oxidative 
phosphorylation. There may be several reasons determining 
such metabolic specialization. First off, compared to astro-
cytes neurons have higher energy need, which can be met 
by oxidative metabolism. Second, neurons may favor glu-
cose utilization through pentose phosphate pathway (PPP) to 
maintain sufficient NADPH levels and antioxidant potential. 
Upon these circumstances, neuronal lactate oxidation allows 
a support to sufficient mitochondrial ATP production with-
out increasing glycolytic activity [90].
Astrocytes are indispensable for supporting both GABAe-
rgic and glutamatergic neurotransmission in brain. The 
available pool of these neurotransmitters depends on the 
glutamine synthesis in astrocytes [91]. In contrast to neu-
rons, astrocytes express pyruvate carboxylase and are able 
to replenish their citric acid cycle intermediates carboxylat-
ing pyruvate to oxaloacetate, what is known as anaplerosis 
[88] [92].
The major waste produced by neuronal activity are carbon 
dioxide and ammonia. While carbon dioxide diffuses across 
BBB, ammonia is taken up by astrocytes and then released to 
neurons [92]. Ammonia enters astrocytes through potassium 
channels and transporters and being processed is released as 
glutamine [93].
In the adult brain, glycogen is deposited in astrocytes 
[94]. Glycogenolysis and the lactate produced in astrocytes 
play a critical role in long-term memory formation [95]. 
It has been demonstrated that pharmacological inhibition 
of either astrocytic glycogenolysis or monocarboxylate 
transporter responsible for neuronal lactate uptake impair 
memory and this impairment can be reversed by administra-
tion of lactate or glucose [96]. Thus, compromised astrocyte 
metabolic functions may result in neuronal dysfunction and 
lead to the development of neurodegeneration. Here, we will 
focus on the most relevant metabolic aspects of astrocytes 
having importance for neurodegenerative diseases.
Alzheimer’s disease
Astrocytic metabolic dysfunction has been suggested be 
a triggering factor for amyloid beta (Aβ) deposition [97]. 
While amyloid deposition has been mostly seen as a con-
sequence of reduced Aβ clearance, increased production of 
amyloidogenic species may take place through metabolic 
regulation of beta and gamma secretase levels [98, 99], or 
aberrant post-translational modification of amyloid precur-
sor protein APP [100]. It has been demonstrated that expo-
sure of cultured astrocytes to amyloid peptides alters their 
glucose uptake and its downstream metabolism in parallel 
with increased hydroperoxide and glutathione release [101]. 
The pro-inflammatory environment typically present in AD 
brain may alter astrocytic metabolism causing increased 
glutamate and ATP release through connexin 43 hemichan-
nels, which in turn could result in microglial activation and 
neuronal vulnerability [102, 103].
Parkinson’s disease and Huntington’s disease
The degenerating brain areas in PD, such as SN, contain 
relatively less astrocytes than other brain areas, making 
dopaminergic neurons potentially more vulnerable to the 
metabolic and energy disturbances [104]. In line with this 
assumption, it has been demonstrated that glucose depri-
vation promotes α-synuclein aggregation [105], whereas 
increased lactate supply inhibits it [106], providing a ration-
ale for involvement of astrocytic metabolic dysfunction in 
PD pathogenesis. Moreover, astrocytes isolated from PD 
animal models expressing mutant α-synuclein or deficient 
for Parkin showed functional and morphological deficits 
of mitochondria, which was linked to astrocytes’ inabil-
ity to support neuronal differentiation [107]. In addition, 
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expression of PD-related A53T mutant α-synuclein in astro-
cytes was found to result in downregulation of glutamate 
transporters and wide-spread gliosis [108]. In the context 
of PD treatment, astrocytes have been shown to convert 
l-DOPA to dopamine [109], and in the striatum, astrocytes 
serve for l-DOPA storage [110]. It is, therefore, likely that 
metabolic and energy disturbances in astrocytes contribute 
to not only development of PD, but also in deteriorating 
treatment responses.
Several lines of research indicate astrocytic contribution 
also in HD. In a mouse model of HD, a deficit of astrocytic 
GABA release through GAT-3 has been thought to cause 
reduced tonic inhibition neuronal output in the striatum 
[111].
Furthermore, in HD mouse models astrocytes have shown 
increased  Ca2+-dependent exocytotic glutamate release 
which correlates with elevated biosynthesis of glutamate 
due to upregulation of astrocytic pyruvate carboxylase [112].
Amyotrophic lateral sclerosis
Both non-cell-autonomous and cell-autonomous mecha-
nisms are implicated in glial cell contribution to ALS 
[113–115], and astrocytes appear to be major determinants 
of ALS progression. Animal studies indicate a toxic gain 
of function in ALS astrocytes, which may converge into 
impaired supportive capacity of astrocytes to motoneurons 
[26, 116]. Subsequently, the initial astrocyte cell-autono-
mous dysfunction may lead to the non-cell-autonomous 
neuronal toxicity [117, 118].
Application of metabolomics, transcriptomics, and lipi-
domics on ALS models indicates significant dysregula-
tion of a number of metabolic pathways in ALS astrocytes 
[119–125]. Metabolomics studies on models composed 
from motoneurons and astrocytes expressing mutant human 
SOD1 revealed disruption of the TCA cycle and glutamate 
metabolism under oxidative stress induced by menadione 
[126]. Furthermore, dysregulation of purine, pyrimidine, 
lysine, and glycerophospholipid metabolism pathways was 
demonstrated in ALS astrocytes co-cultured with motoneu-
rons. In this model, glutamate exposure caused significant 
alterations in the astrocyte metabolic fingerprint and associ-
ated with decreased lactate levels by affecting lactate efflux 
from astrocytes [127]. Moreover, these findings correlate 
with the data from CSF analyses of human ALS patients 
[120]. Importantly, ALS in human patients has been asso-
ciated with hypermetabolism, possibly involving aberrant 
astrocytic mitochondrial metabolism [128], which is present 
already at the pre-symptomatic state in SOD1 mutant mouse 
models and may thus have a key role of in early disease 
pathogenesis [129].
Analysis of ALS models expressing mutant SOD1 
reveals prominent astrocytic alterations linked to metabolic 
dysregulation due to impairment of the astrocyte lactate 
transport and pro-nerve growth factor-p75 receptor signal-
ing [129]. In addition, aberrant activation of metabotropic 
receptor 5 mGluR5 has been demonstrated in ALS astro-
cytes causing persistent elevation of intracellular calcium 
[130]. More recently, a specific chronic activation of the 
α2-Na/K ATPase/α-adducin complex in ALS astrocytes has 
been demonstrated, resulting in biased energy metabolism 
and acquisition of pro-inflammatory phenotype [131].
It has been demonstrated that astrocytes also potentially 
regulate neuronal proteostasis by affecting autophagic 
degradation pathways. The ability of conditioned medium 
from ALS-patient iPSC-derived astrocytes to modulate the 
autophagy pathway neuronal cells has been linked to the 
decreased expression of LC3-II and concomitant increase 
in the expression of SOD1 [132].
Overall, the current research demonstrates that astrocytic 
non-cell-autonomous and cell-autonomous mechanisms 
including metabolic dysfunction and related changes in gene 
expression play a central role in pathogenesis of neurode-
generative diseases, and identification of molecular targets in 
astrocytes can serve for designing therapy that could prevent 
or slow down the disease progression.
Astrocytes in the inflammation associated 
with neurodegeneration
Although the exact mechanisms of neurodegeneration are 
not known, recent data have identified the inflammatory pro-
cesses tightly linked to multiple neurodegenerative pathways 
[133]. Regardless of the immune reaction within the CNS, it 
always involves astrocytes and microglia [134], the resident 
immune cells of the CNS. Under physiological conditions, 
astrocytes are key cells for the maintenance of homeostatic 
balance [135]. However, under pathological inflammatory 
state, they may produce neurotoxic factors that amplify the 
disease state, indicating the persistence of inflammatory 
stimuli or failure in normal resolution mechanisms [136]. 
This can result in the production of neurotoxic mediators, 
such as cytokines and interleukins [137], which are associ-
ated with several neurodegenerative diseases such as AD, 
PD, and ALS. The inflammation associated with these dis-
eases is not typically the initiating factor of neurodegen-
eration. However, the emerging evidence on the sustained 
inflammatory response associated with the contribution of 
astrocytes in disease progression suggests contributory role 
for neuroinflammation in neuronal dysfunction and death.
Traditionally, increased GFAP expression has been con-
sidered as a hallmark of astrocyte activation in neurode-
generative disorders [138]. In addition, increased levels of 
pro-inflammatory cytokines such as INF-γ, IL-1β, IL-6, and 
TNFα are known to result in classical astrocyte activation, 
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leading to increased activation of NF-κB pathway, produc-
tion of ROS and NO, and further release of IL-1β, IL-6, and 
TNFα. On the contrary, augmented levels of IL-4 and IL-13 
induce an alternative activation with increased secretion of 
IL-4 and decreased production of ROS and NO (Fig. 1d). 
However, astrocyte deactivation, including reduced immune 
surveillance and pro-inflammatory signaling, is mediated 
through high levels of IL-10 and TGF-β [139].
Alzheimer’s disease
Neuroinflammation is a major contributor to AD, driven by 
the activation of microglia and astrocytes. A recent study 
of CSF markers from several hundred individuals with 
mild cognitive impairment and patients with AD dementia 
revealed increased levels of YKL-40, ICAM-1, VCAM-1, 
IL-15, and Flt-1 during the pre-clinical, prodromal, and 
dementia stages of AD [140]. There was a correlation of 
these biomarkers with increased CSF levels of total tau, 
especially for YKL-40, a glycoprotein secreted by micro-
glia and astrocytes. Interestingly, high astrocytic expression 
of IL-15 has also been shown to promote tissue damage in 
multiple sclerosis and following brain ischemia [141].
Aβ, the main pathological hallmark of AD, activates 
astrocytes to release chemokines and cytokines, and in an 
interaction with the increased levels of pro-inflammatory 
cytokines even increases the production of Aβ in neurons 
and astrocytes [142]. In fact, hypertrophic reactive astrocytes 
are strongly associated with Aβ pathology, as they accu-
mulate around Aβ plaques, and are seen [143]. Especially, 
the pro-inflammatory A1 phenotype of astrocytes is seen in 
post-mortem tissue from AD patients. While Aβ has been 
demonstrated to induce a pro-inflammatory profile, and 
even astrogliosis in AD, it is not clear whether it is Aβ that 
induces this phenotype [23] [144].
In AD, neuroinflammation is characterized by the accu-
mulation of cytokines such as IL-1β, IL-6, TNF-α, or 
TGF-β, which can, through activation of β- and γ-secretase 
activity, further contribute to cerebral amyloid deposition, 
augmentation of APP expression, Aβ formation, and finally 
to recruitment and activation of microglial cells [145].
Pro-inflammatory astrocyte activation appears to be 
linked to the release of synaptotoxic factors and loss of 
glutamate regulation. Dysregulation of  Ca2+ homeostasis 
is thought to play the central role in these events. Due to 
the complexity of the  Ca2+ balancing mechanisms, any 
malfunction in the regulatory checkpoints may contribute 
to the overall pathological alterations in neurodegenerative 
diseases. The  Ca2+/calmodulin-dependent protein phos-
phatase, calcineurin has been suggested to provide a l link 
between  Ca2+ dysregulation and astrocyte activation [146]. 
Calcineurin is highly expressed by subsets of activated astro-
cytes in both humans and animal models, resulting in the 
consecutive NFAT activation and contributing to the AD 
neuropathology [147].
Parkinson’s disease
One of the key aspects in PD pathophysiology is neuroin-
flammation, including presence of reactive astrocytes, in 
the substantia nigra pars compacta [148]. This is thought 
to be a downstream response to the death of dopaminergic 
neurons, even though there is also increasing amount of evi-
dence, suggesting that astrocytes have an initiating role in 
PD pathophysiology [149].
Several genes implicated in PD pathology, including 
SNCA, DJ-1, PLA2G6, ATP13A2, LRRK2, PINK, and Par-
kin, have been demonstrated to play a role in the origination 
and regulation of astrocyte activation in response to inflam-
matory stimuli [149]. Both α-synuclein and DJ-1 have been 
shown to affect the astrocytic TLR4 signaling [150–152]. 
Furthermore, if looking at the secreted pro-inflammatory 
mediators, Parkin expression is known to be modified by 
IL-1β and TNF-α stimulation [153] and DJ-1 has been 
shown to regulate astrocyte activation by IFN-γ   [154]. 
Finally, functional ATP13A2 expression prevents NLRP3 
inflammasome activation [155].
Interestingly, a recent study demonstrated that post-mor-
tem brain samples from PD patients display increased astro-
cytic senescence. Furthermore, paraquat, a known chemi-
cal to cause parkinsonism, induced astrocytic senescence 
and senescence-associated secretory phenotype with robust 
secretion of numerous inflammatory cytokines, chemokines, 
growth factors, and proteases both in in vitro and in in vivo 
settings [156]. Another recent report studying transplanta-
tion of neural progenitors in PD utilized co-transplantation 
of rat astrocytes and showed increased anti-inflammatory as 
well as decreased pro-inflammatory profile associated with 
behavioral improvement in the animals [235]. This further 
emphasizes the dual role of astrocytes in the neurodegenera-
tion as astrocytes can either support the neurons or cause 
their degeneration.
Amyotrophic lateral sclerosis
ALS is considered to be a non-cell-autonomous disease 
with substantial involvement of astrocytes [157]. Post-
mortem studies of ALS patients have revealed increased 
GFAP expression in the motor cortex, motor nuclei of the 
brain stem, the corticospinal tract, and the ventral horn of 
the spinal tract [158]. Furthermore, astrocytic production 
of pro-inflammatory mediators, such as type 1 interferons, 
TGF-β1, and prostaglandin  D2, has been demonstrated to 
be upregulated in ALS-patient post-mortem tissues and in 
ALS models based on embryonic stem cell-derived human 
astrocytes [113, 159, 160]. In addition, the astrocytic NLRP3 
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inflammasome expression has been shown to be increased, 
leading to augmented IL-1β production in the post-mortem 
tissues of sALS patients [161]. Most recently, the advances 
in the patient neuroimaging have allowed direct visualization 
of neuroinflammation in ALS. Although in the post-mortem 
tissues from ALS patients, astrocytosis is seen in parts of the 
corticospinal tract other than pons [162], PET imaging with 
[11C]-DED, a commonly used marker of activated astro-
cytes, was able to demonstrate increased uptake rate in pons 
and white matter [163], which may reflect corticospinal tract 
astrocytosis. Finally, a strong astrocytic A1-phenotype has 
been discovered in the motor cortex of ALS patients, further 
highlighting the pro-inflammatory phenotype of astrocytes 
in the areas affected by ALS [23].
Huntington’s disease
Increased susceptibility to pro-inflammatory stimulation has 
been demonstrated in several mouse models of HD [164].
The enhanced inflammatory response in the brain was 
observed only in models with expression of mHTT includ-
ing glial cells. The studies on primary astrocytes revealed 
increased IkB kinase activity, resulting in prolongation of 
NF-kB activation and upregulating pro-inflammatory fac-
tors, particularly TNF-α. Importantly, enhanced activation 
NF-kB-p65 was observed in astrocytes of patients and mice 
with HD [164]. Further attempts to block soluble TNF-α 
signaling using a dominant negative inhibitor XPro1595 
caused decrease of TNF-α in the cortex and striatum, result-
ing in increased neuronal density and improved motor func-
tion. In addition, diminished amount of mutant HTT aggre-
gates, and decreased gliosis was evident in brains of R6/2 
mice [165].
Astrocytes and oxidative stress 
in neurodegenerative diseases
Brain metabolism uses vast amounts of oxygen, and thus 
also produces free oxygen radicals that may damage the 
cells. At the same time, brain has relatively low antioxidant 
defense mechanisms and high incidence of peroxidation sub-
strates, such as enrichment of unsaturated fatty acids and 
redox active transition metals [166]. Thus, the brain is one 
of the most susceptible tissues for oxidative damage. Oxida-
tive stress plays an important role in various neurodegenera-
tive disorders, in which age is one of the main risk factors 
and cumulative oxidative stress is considered as one of the 
mechanisms driving the age-related changes [167].
The level of oxidative stress in tissues is dependent on the 
balance between two separate mechanisms: 1) production of 
ROS (reactive oxygen species) and 2) the ability of antioxi-
dant defense mechanisms to scavenge ROS. Yet, ROS are 
not only deleterious, but also essential signaling molecules 
needed for many adaptive processes and during develop-
ment [168, 169]. Oxidative stress in the brain is thus not 
only related to the level of oxidative damage but also to the 
intriguing redox signaling, which can, for example, regulate 
growth of neural progenitor cells [170] and control axonal 
pathfinding and regeneration [171].
The production of ROS is directly linked to the metabolic 
activity of the cells, and specifically, the mitochondrial res-
piratory activity as mitochondria is the main source of ROS 
[172, 173]. Apart from mitochondria, also peroxisomes pro-
duce ROS as byproducts of their metabolic processes such as 
fatty acid oxidation [174]. Mitochondrial ROS are produced 
as a consequence of normal respiratory chain (RC) activity. 
While the normal respiratory function leads to relatively low 
ROS generation, RC defects may increase ROS production 
significantly (reviewed in Ref. [116]).
As mitochondria are major producers of ROS, they are 
also well equipped with defense mechanisms for ROS scav-
enging (reviewed in Ref. [118]).
Oxidative stress in astrocytes
Astrocytes are glycolytic in their metabolism, to the extent 
that they survive without active respiratory chain [175]; 
thus, neurons have been considered as the major ROS pro-
ducers in the brain. However, recent reports have shown that 
astrocytes can contribute to the redox status of the brain 
both directly by producing ROS and indirectly by affecting 
neuronal metabolism. Neurons rely on astrocytes for lac-
tate supply and diminished lactate supply from astrocytes is 
likely to alter the oxidative microenvironment in the brain by 
increasing neuronal respiratory activity and reducing neu-
rovascular coupling [176]. In addition, upon inflammation 
ROS is produced by both activated microglia and astrocytes 
to serve in the immune response and to trigger signaling 
cascades [177, 178]. Several antioxidant response pathway 
genes are regulated by the transcription factor Nrf2, which 
binds to the antioxidant response element (ARE) present 
in these genes. In normal physiological conditions, Keap1 
targets Nrf2 for ubiquitin-mediated degradation; however, in 
oxidative conditions, Keap1 is not able to bind Nrf2 lead-
ing to accumulation of Nrf2 in the nucleus and induction of 
ARE-containing genes [179, 180]. This Nrf2–ARE path-
way is particularly weak in neurons, whereas astrocytes both 
show strong response to Nrf2 activation and have higher 
expression of ARE-containing genes than neurons (Fig. 1e) 
[181]. Isolated neurons are known to possess very limited 
antioxidant defenses, including low catalase and GSH lev-
els, both regulated by Nrf2, and Nrf2 deficiency does not 
affect their expression [182]. Astrocytes on the other hand 
are much more resistant to oxidative insults. They have high 
capacity for production and storage of GSH and oxidative 
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stress increases GSH release from astrocytes. The GSH 
released from astrocytes is degraded and the cysteine-rich 
products are taken up by neurons to be used as building 
blocks for neuronal GSH synthesis in a process regulated 
by Nrf2 [183, 184]. Nrf2 deficiency also increases astrocyte 
vulnerability to oxidative stress [182].
Despite their low antioxidant defenses but high mito-
chondrial respiratory activity and consequently relatively 
high ROS production, post-mitotic neurons survive and 
remain functional for decades. This is thought to be achieved 
through antioxidant support from surrounding astrocytes 
[185].
Alzheimer’s disease
Aβ plays a key role in oxidative stress induction in AD and 
astrocytes seem to be involved in this. Aβ exposure in neu-
ron–astrocyte co-cultures leads to a loss of mitochondrial 
membrane potential and increased ROS production in astro-
cytes but not in neurons [186]. The increase in ROS is due 
to the activation of astrocytic NADPH oxidase, as inhibition 
of it blocks the ROS production and protects neurons [186]. 
The increased ROS due to activated NADPH oxidase further 
activates PARP, which leads to decreased NAD levels and 
metabolic failure in astrocytes further leading to neuronal 
death [187]. These data from rodent models strongly sug-
gest that astrocytes have a central role in oxidative stress 
induction in AD. Human data are still scarce; however, our 
recent report from PSEN1 mutant patient astrocytes showed 
that also human AD patient astrocytes manifest Aβ deposits 
and altered metabolism with increased ROS production and 
these result in reduced neuronal support [188].
Oxidative stress directly affects  Ca2+-homeostasis [189], 
which is one of the hallmarks of astrocytes and impaired in 
AD. In astrocytes, increased ROS production together with 
 Ca2+ leakage from ER leads to opening of the mitochondrial 
permeability transition pore and transient depolarization of 
mitochondria, resulting in loading of cellular  Ca2+ from 
ER to mitochondria [190]. The transient events were not 
detrimental; however, they eventually lead to complete loss 
of membrane potential and necrotic cell death and further 
increase in ROS production [190].
Astrocytic activation of transcription factor Nrf2 results 
in upregulation of antioxidant responses spreading to sur-
rounded neurons [191, 192]. It has been demonstrated that 
lentiviral Nrf2 gene transfer causes a robust reduction in 
astrocytic activation and induction of Nrf2 target gene heme 
oxygenase 1 [193]. Finally, activation of the Nrf2 pathway 
by small molecules has been shown to confer protection in 
several neurodegenerative disorders, including AD and PD 
[194], and studies using mice with astrocyte-specific over-
expression of Nrf2 prove that this neuronal protection is 
mediated by astrocytes, further signaling the importance of 
astrocytes in oxidative stress and neurodegeneration [184, 
195].
Amyotrophic lateral sclerosis
RC dysfunction in an SOD1 mutant rat model for ALS has 
been shown to lead to increased ROS production by astro-
cytes and motor neuron loss, which can be prevented by 
treating the astrocytes with antioxidants, suggesting a role 
for astrocytes in induction of oxidative stress also in ALS 
[196].
NF-κB transcription factors are central in inflammation 
and activated mainly by pro-inflammatory stimulation, 
which is present in many neurodegenerative diseases. How-
ever, also ROS has a strong role in regulating NF-κB signal-
ing, and again, certain NF-κB-regulated genes are involved 
in regulating cellular ROS levels [197]. The most direct way 
for NF-κB to regulate cellular ROS levels is through acti-
vating antioxidant genes such as SOD2, SOD1, and thiore-
doxins [198–200]. However, as inflammation stimulates 
ROS production, NF-κB can activate also genes that lead to 
increased ROS. These include NADPH oxidase and induc-
ible nitric oxide synthase (iNOS) [201, 202].
How ROS regulates NF-κB signaling in astrocytes is 
more complex. First of all, ROS has been reported to stimu-
late NF-κB in the cytoplasm, but inhibit it in the nucleus and 
many of the interactions of ROS and NF-κB are cell type 
and even astrocyte-specific [203]. Oxidation of cysteines is 
the most well characterized way that ROS affects NF-κB 
pathway. The initial reactions to sulfenic acid are usually 
reversible by antioxidants, but further oxidation leads to 
irreversible changes [203]. ROS can inhibit NF-κB DNA 
binding by direct oxidation of a cysteine of p50 [204]. The 
same cysteine can also be s-nitrosylated by NO produced by 
iNOS, which is activated by NF-κB, thus creating a nega-
tive feedback loop [205]. NF-κB activation may also further 
induce COX-2 and phospholipase A2 expression and pro-
mote inflammation [206].
Modelling astrocytic dysfunction in human 
iPSC platforms
The majority of the current human data from neurodegenera-
tive diseases originates from post-mortem samples, repre-
senting thus only the end stage of the disease. Novel method-
ologies have enabled the generation of comprehensive iPSC 
cell libraries [207], which will in the future be an invaluable 
model resource for studying neurodegeneration. For exam-
ple, iPSC-based studies have shown aberrant morphological 
changes in AD astrocytes [208], as well as APOE-related 
neurotrophic and synaptic disturbances [19]. Our recent 
results further confirm the central role of astrocytes in 
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AD and synaptic defects. We studied the consequences of 
mutant PSEN1 ΔE9 in patient iPSC-derived astrocytes and 
how it could be linked to AD pathology [188]. Our PSEN1 
ΔE9 astrocytes demonstrated increased Aβ production and 
oxidative stress while showing reduced lactate production. 
Furthermore, the PSEN1 ΔE9 astrocytes influenced the 
 Ca2+ signaling in healthy neurons. Both the glutamate and 
GABA-induced  Ca2+ responses were reduced in neurons 
cultured with AD astrocytes in comparison with when the 
neurons were cultured with isogenic control astrocytes, sug-
gesting that synaptic abnormalities indeed occur early in 
the disease course via astrocyte dysfunction. In addition, 
we were able to demonstrate that PSEN1 ΔE9 mutant astro-
cytes have altered cytokine secretion after pro-inflammatory 
stimulation [188].
In addition, the novel stem cell-based BBB models are 
very promising [209–211]. They have already resulted in 
advances in HD studies, showing that hiPSC-derived micro-
vascular ECs had intrinsic abnormalities in angiogenesis and 
barrier properties [212]. In another recent study, a human 
BBB model based on hiPSCs from a patient carrying a muta-
tion in transporter MCT8 revealed a decreased transport of 
l-triiodothyronine affecting neuronal function [213]. Studies 
to model BBB in AD, stroke, and traumatic brain injury are 
being developed [214]. hiPSC-based BBB models hold great 
promises for disease modeling and drug development and 
could provide new insights into how vascular dysfunction 
contributes to neurodegenerative diseases.
New iPSC techniques have also been exploited in ALS 
studies. Studies on ALS astrocytes of SOD1 mice and sALS 
patients as well in human ALS iPSC-derived astrocytes 
revealed elevated levels of connexin 43, which were associ-
ated with increased intracellular  Ca2+ levels that regulate 
motor neuron survival [215]. One of the key roles of astro-
cytes is to support motoneurons, and importantly, a recent 
study discovered a neuronal help-me signal, which seems to 
be disrupted in ALS-patient-derived iPSC astrocytes and to 
lead to impaired STAT3 activation [118]. In this study, cell-
autonomous mechanisms were found to diminish EphB1-
ephrin-B1-mediated reverse signaling and STAT3 activation 
in ALS astrocytes [118]. The deficit was observed to cause a 
failure in maintenance of neuroprotective status that is nor-
mally induced by neuronal signals upon injury in healthy 
controls. Moreover, the detailed analysis of ALS astrocytes 
revealed an increased expression of PHLDA3, a regulator 
of Akt phosphorylation previously linked with cell death 
and degeneration in response to oxidative stress [216]. Thus, 
astrocytes in ALS and potentially in other neurodegenera-
tive diseases may display loss-of-function type changes that 
could be valuable in future development of more efficient 
therapies.
The iPSC-based models revealing a central role of astro-
cyte dysfunctions in pathogenesis of neurodegenerative 
diseases makes them attractive target for drug discovery. 
Due to complexity of pathophysiological mechanisms, pre-
clinical models that adequately reflect this are indispensable 
for the development of novel pharmacological treatments 
[217]. Currently, a number of in vitro models clearly indicate 
a pivotal role of astrocytes modulating neuronal responses, 
including their ability to survive environmental stress.
An important aspect on the drug discovery is the safety 
issues, particularly neurotoxicity in humans [218]. The 
induction of seizures is among the main adverse effects 
causing a failure of clinical trials. In a study, where hiPSC- 
derived neurons were co-cultured with astrocytes, activation 
of pathways related to AMPA and NMDA receptors, neu-
ronal polarity, and axon guidance was demonstrated [219]. 
These results indicate that hiPSC-derived astrocytes pro-
mote neuronal susceptibility to convulsant drugs and that 
co-culture of hiPSC-derived neurons with hiPSC-derived 
astrocytes allows for a pre-clinical risk assessment of drug-
induced seizures.
Astrocytes differentiated from human ESCs and iPSC 
have been used to screen compound libraries aiming at 
identification of molecules that could counteract oxidative 
stress, a common denominator in neurodegeneration [220]. 
Here, in a study by Ishii et al., a total of 4100 FDA approved 
drugs and compounds were screened and 9 of the 22 hits 
were validated in astrocytes differentiated from human iPSC. 
The protective mechanism proposed for the validated hits 
was implicating activation of antioxidant response though 
induction of Nrf2.
Transplantation of glial progenitor cells 
and astrocytes
Animal models are used extensively to validate therapeutic 
targets, but confirmation of cellular and molecular mecha-
nisms in human cells in vivo could increase the probabil-
ity of successful target validation and drug development. 
Human glial chimeras may provide useful models for assess-
ing the role of glia targets in human cognitive processing. 
The ability to construct the mice with glia generated from 
human ESCs and iPSCs allows the establishment of human 
glial chimeric mice with glia from defined disease genotypes 
and phenotypes. The capability promises to significantly 
advance our understanding of the contribution of glia to the 
pathogenesis of a wide variety of neurological disorders, 
many of which have simply been assumed to be entirely 
neuronal by origin.
Chimeric glial brains can be generated in vivo by a neo-
natal transplantation of human glial progenitors (A2B5+/
PSA–NCAM cells obtained from 17- to 22-week-old human 
fetuses). Maturated recipient’s brains show large numbers 
and high proportions of both human glial progenitors and 
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astrocytes, which retain specific hominid features despite of 
integration with the host astroglia and formation of gap junc-
tions. The chimeric mice show increased performance in a 
number of behavioral tests such as maze navigation and fear 
conditioning [12], indicating the special features of human 
astrocytes and the value of such chimeric mouse models.
When human glial progenitor cells are transplanted into 
congenitally hypomyelinated shiverer mice, which have defi-
cits in myelin generation and die by 18–21 weeks of age, the 
lethal phenotype is rescued and neurological performance 
improved [221]. The follow-up of 1 year after transplanta-
tion revealed massive expansion of human glia, outcompet-
ing host cells [222].
Thus, the models based on disease-specific iPSC-derived 
human glial chimeras may provide an opportunity for bet-
ter understanding of astrocytic dysfunction in a broad range 
of neurodegenerative and neuropsychiatric disorders [223].
A chimeric model comprising neonatal engraftment of 
human glial progenitor cells derived from mutant hunting-
tin transduced fetal hGPCs into immunodeficient mice has 
been established [224]. In these animals, striatal neurons are 
hyperexcitable and they display worse motor performance 
than controls. In contrast, striatal transplantation of normal 
glia into R6/2 HD mice counteracts the disease phenotype 
by restoration of interstitial potassium homeostasis, improv-
ing electrophysiological and behavioral test results, slowing 
down disease progression and extending the survival.
Recently, a human glia chimeric model was established 
by transplanting astroglia progenitors differentiated from 
iPSC lines of childhood-onset schizophrenic subjects [225]. 
These glial chimeras developed abnormal astrocytic mor-
phology and hypomyelination compared to glial chimeras 
generated with cells derived from control iPSC lines. An 
impairment in the expression of differentiation-associated 
genes was evident and glial progenitors of schizophrenic 
subjects and corresponding chimeric mice demonstrated 
a broad range of behavioral and sleep abnormalities. Even 
though schizophrenia is not a neurodegenerative disease, this 
study shows further evidence for the importance of astro-
cytes in brain diseases.
The demonstrated non-cell-autonomous mechanisms 
in ALS provide a rationale for developing therapeutic 
approaches based on transplantation of glial progenitors. In 
a recent study human neural progenitor, cells engineered to 
produce GDNF were transplanted into the G93A SOD1 ALS 
rat cortex [226]. The transplanted cells maturated to astro-
cytes and released GDNF. The protection of motoneurons, 
delayed disease onset, and extended survival by transplanted 
GDNF producing progenitors were evident.
Spinal neural progenitor cells derived from healthy fALS 
and sALS iPSCs have been transplanted into cervical spi-
nal cord of adult SCID mice [28]. Nine months later differ-
entiated human astrocytes were found in large areas of the 
spinal cord, replacing host astrocytes and forming contacts 
with neurons. Importantly, both fALS and sALS cell trans-
plantations caused reduction in motoneuron numbers and 
remaining motoneurons showed reduced inputs from inhibi-
tory neurons and exhibited disorganized neurofilaments and 
aggregated ubiquitin. In addition, the cellular pathology in 
the spinal cord was accompanied with motor deficits. These 
results indicate that both fALS and sALS iPSC-derived 
astrocytes are capable to induce ALS-like pathological phe-
notype [227]. Importantly, transplantation into wt and ALS 
spinal cord showed no gross differences in the engraftment 
or gene expression in the differentiated human astrocytes, 
suggesting that the phenotype of transplanted glial progeni-
tors is independent from the neurodegenerative environment 
supporting thus clinical transplantations into ALS patients 
[228].
Furthermore, HD patient-specific iPSCs were differen-
tiated into neural progenitor cells and functional neurons 
in vitro [229]. When transplanted in vivo, they gave rise 
to neurons in the adult mouse brain. In parallel, astrocytes 
derived from HD iPSCs showed increased cytoplasmic vacu-
olation. Altogether, these results support feasibility to reca-
pitulate HD phenotype under basal conditions what has been 
demonstrated in primary cells from HD patients.
In studies, where transplantation of glial-rich neural pro-
genitors derived from human iPSCs was found to be ben-
eficial, the potential therapeutic mechanism was assumed 
take place via activation of AKT signaling [230]. In one 
study, where primary glial-restricted precursor cells were 
transplanted focally into cervical spinal cord of a trans-
genic ALS rat, concomitant reduction of gliosis, extended 
survival, attenuated motor neuron loss and improved motor 
functions was observed to be partially mediated by astrocyte 
glutamate transporter GLT1 [231].
Human fetal-derived neural progenitor cells have been 
shown to survive well and mainly differentiate into astro-
cytes when transplanted into aging rat spinal cord [232]. 
Interestingly, differentiation into astrocytes was consider-
ably more efficient in aged rats (500 and 600 days) than 
when using younger animals (100 and 200 days), possibly 
because aged environment may have more factors that stim-
ulate astrocyte maturation compared to young adults. The 
differentiated astrocytes of the transplantation prevented the 
motoneuron loss that is associated with aging, even though 
improved motor performance was not evident.
One approach to obtain healthy, potentially therapeutic 
astrocytes into the CNS is injection of human mesenchy-
mal stem cells (MSCs) into the cerebrospinal fluid. When 
symptomatic transgenic ALS rats received such injection, 
MSCs infiltrated into the nervous parenchyma and migrated 
substantially into the ventral gray matter [233]. Importantly, 
the injected MSCs efficiently differentiated into astrocytes, 
reduced motoneuron loss, and prolonged survival. The 
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beneficial effect of human MSC-derived astrocytes was 
possibly mediated by reduced inflammation, since the neu-
roprotection correlated with the inhibition of microglial pro-
liferation and reduction of COX-2 and NOX-2 expressions.
Transplantation of precursor cell-derived astrocytes has 
also been studies in a rat model of PD. The astrocytes were 
generated in vitro by directed differentiation of glial precur-
sors. The transplantation into striatum of the 6-hydroxydo-
pamine lesioned rat model restored HT expression rescued 
GABAergic interneurons and improved behavioral recovery 
[234]. It is thought that transplanted cells produced benefi-
cial trophic factors and antioxidants. Further studies have 
explored cografting astrocytes, derived from the midbrain 
and demonstrated that they remarkably enhanced neural 
progenitor cell differentiation into maturated DA neurons 
and promoted DA neuron engraftment in PD rats for at least 
6 months after transplantation [235].
A number of studies have investigated astrocyte transplan-
tation in AD models. When astrocytes isolated from adult 
and neonatal mice were transplanted into the hippocampi of 
AD model APdE9 mice most of them were found near Aβ 
deposits and internalized human Aβ immunoreactive mate-
rial [236]. In the follow-up study, a significant reduction in 
Aβ burden was observed after 2 months in parallel colocali-
zation with transplanted astrocytes, and the remaining Aβ 
deposits showed fragmentation [237]. The mechanism dem-
onstrated was associated with astrocytic expression of Aβ 
degrading proteases such as neprilysin (NEP), angiotensin-
converting enzyme-1 (ACE-1), and endothelin-converting 
enzyme-2 (ECE-2).
Another approach by autologous transplantation of glia 
cells isolated from intestine—enteric glial cells (EGCs) has 
demonstrated an improvement in neuropathology and resto-
ration of cognitive deficits in of a rat model of Aβ-induced 
neurodegeneration [238].
Conclusions
Astrocytes have been shown to take active part in nearly all 
CNS functions and participate both in initiation and progres-
sion of neurodegenerative disease. As human astrocytes are 
much more complex than their rodent counterparts, human 
models are needed to be able to better understand the role of 
astrocytes in human neurological disease. Moreover, there 
is strong evidence, indicating that activation of microglia 
precedes the pro-inflammatory activation of astrocytes in 
rodents. Considering that inflammation is involved in aging 
and most of the brain diseases, models including both human 
astrocytes and human microglia that interact with human 
neurons are going to further reveal the multiple functions of 
human astrocytes. Thus, the novel human stem cell-based 
models are indispensable to discover pathological mecha-
nism and for development of therapeutic strategies.
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